Profiles of Leading Women Scientists on AcademiaNet.
Search among the members of the Leopoldina for experts in specific fields or research topics.
Image: Markus Scholz | Leopoldina
Nobel Prize for Physiology or Medicine 2023
Year of election: | 2022 |
Section: | Human Genetics and Molecular Medicine |
City: | Mainz |
Country: | Germany |
Research Priorities: mRNA therapy, mRNA vaccines, neurodegenerative diseases
Katalin Karikó is a Hungarian American (US) neuroscientist and biochemist who recognised at an early stage the potential of synthetically produced mRNA for the treatment of immunological and oncological diseases and of vaccine development. Katalin Karikó has made a significant contribution to the basic research on which current mRNA technology is based.
The biochemist searched for ways to prevent the inflammatory processes triggered by synthetic mRNA, which have stood in the way of a medical application of mRNA technology for a long time. She observed that the inflammation reaction can be avoided pseudouridine with its different spatial arrangement was incorporated into the mRNA instead of uridine, the nucleoside building block . Embedded in nanolipid particles, an mRNA modified in this way forms the basis for the mRNA vaccines that have been used worldwide since the end of 2020 and have since immunised millions of people against the SARS-CoV-2 virus. With this research Katalin Karikó has laid the foundations of a new technology. Future possible applications are so diverse that they are hard to estimate at present.
The scientist is now focusing on extending mRNA technology to therapeutic proteins for treating tissue injuries and above all for treating tumour diseases. With this aim, Katalin Karikó continues to conduct basic research to obtain a deeper understanding of mRNA technology.
Since her PhD, the biochemist has also been interested in the causes of neurodegenerative diseases, in which a certain section of the genetic code in the DNA is present in multiple repetitions and thus leads to faulty RNA and ultimately to neurotoxic proteins. However, mutated RNA not only produces a defective protein, but can also exert further toxic effects, for example by disrupting the folding of the protein which is crucial for a protein's action. These genetically determined diseases are also referred to as RNA toxicity diseases. In addition to Huntington's disease, they include Friedreich's ataxia, fragile X ataxia, movement disorders of the central nervous system and forms of amyotrophic lateral sclerosis (ALS). Katalin Karikó's team is researching such faulty RNA protein interactions with their neurotoxic effects at the molecular level in order to identify target molecules for innovative treatment approaches.